![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
B Poddevin, JF Riou, F Lavelle and Y Pommier
Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
The mechanisms of action of intoplicine (RP-60475), a 7H- benzo[e]pyrido[4,3-b]indole derivative that is presently in early clinical trials, have been investigated. Intoplicine induced both topoisomerase I- and II-mediated DNA strand breaks, using purified topoisomerases. The topoisomerase cleavage site patterns induced by intoplicine were unique, relative to those of camptothecin, 4'-(9- acridinylamino)methanesulfon-m-anisidide (m-AMSA), and other known topoisomerase inhibitors. Both topoisomerase I- and II-induced DNA breaks decreased at drug concentrations higher than 1 microM, which is consistent with the DNA-intercalating activity of intoplicine. DNA damage was investigated in KB cells in culture by using alkaline elution. Intoplicine induced single-strand breaks (SSB) in a bell- shaped manner with respect to drug concentration (maximum frequency at 1 microM approximately 220 rad-equivalents). SSB formation was fast, whereas reversal after drug removal was slow. Similar bell-shaped curves were obtained for DNA double-strand breaks (DSB) and DNA-protein cross-links. SSB and DNA-protein cross-link frequencies were approximately equal, and no protein-free breaks were detectable, indicating the protein concealment of the breaks, as expected for topoisomerase inhibition. Comparison of SSB and DSB frequencies indicated that intoplicine produced a significant amount of SSB not related to DSB, which is consistent with concomitant inhibition of both DNA topoisomerases I and II in cells. Data derived from resistant cell lines indicated that multidrug-resistant cells were cross-resistant to intoplicine but that m-AMSA- and camptothecin-resistant cells were sensitive to intoplicine. Hence, intoplicine might circumvent topoisomerase I-mediated and topoisomerase II-mediated resistance by poisoning both enzymes simultaneously.
This article has been cited by other articles:
|
|
 |
|
  D. J. Baker, G. Wuenschell, L. Xia, J. Termini, S. E. Bates, A. D. Riggs, and T. R. O'Connor Nucleotide Excision Repair Eliminates Unique DNA-Protein Cross-links from Mammalian Cells J. Biol. Chem., August 3, 2007; 282(31): 22592 - 22604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nakamura, H. Sugumi, A. Yamaguchi, T. Uenaka, Y. Kotake, T. Okada, J. Kamata, J. Niijima, T. Nagasu, N. Koyanagi, et al. Antitumor Activity of ER-37328, a Novel Carbazole Topoisomerase II Inhibitor Mol. Cancer Ther., January 1, 2002; 1(3): 169 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R van Gijn, R. Lendfers, J. Schellens, A Bult, and J. Beijnen Dual topoisomerase I/II inhibitors Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3): 92 - 108. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Guano, P. Pourquier, S. Tinelli, M. Binaschi, M. Bigioni, F. Animati, S. Manzini, F. Zunino, G. Kohlhagen, Y. Pommier, et al. Topoisomerase Poisoning Activity of Novel Disaccharide Anthracyclines Mol. Pharmacol., July 1, 1999; 56(1): 77 - 84. [Abstract] [Full Text]
|
|
|
|
|
|
G. Kohlhagen, K. D. Paull, M. Cushman, P. Nagafuji, and Y. Pommier Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison Mol. Pharmacol., July 1, 1998; 54(1): 50 - 58. [Abstract] [Full Text]
|
|
|
|
|
|
M. Valenti, W. Nieves-Neira, G. Kohlhagen, K. W. Kohn, M. E. Wall, M. C. Wani, and Y. Pommier Novel 7-Alkyl Methylenedioxy-Camptothecin Derivatives Exhibit Increased Cytotoxicity and Induce Persistent Cleavable Complexes Both with Purified Mammalian Topoisomerase I and in Human Colon Carcinoma SW620 Cells Mol. Pharmacol., July 1, 1997; 52(1): 82 - 87. [Abstract] [Full Text]
|
|
|
|
|
|
F. Boege, T. Straub, A. Kehr, C. Boesenberg, K. Christiansen, A. Andersen, F. Jakob, and J. Köhrle Selected Novel Flavones Inhibit the DNA Binding or the DNA Religation Step of Eukaryotic Topoisomerase I J. Biol. Chem., January 26, 1996; 271(4): 2262 - 2270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Knab, J. Fertala, and M.-A. Bjornsti A Camptothecin-resistant DNA Topoisomerase I Mutant Exhibits Altered Sensitivities to Other DNA Topoisomerase Poisons J. Biol. Chem., March 17, 1995; 270(11): 6141 - 6148. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
